Glucotrack, Inc. Announces $3.1M Registered Direct Offering

What Happened

• On September 24, 2026, Glucotrack, Inc. entered a Securities Purchase Agreement for a registered direct offering of securities to institutional investors. The Offering consists of 169,388 shares of common stock and pre-funded warrants to purchase up to 1,350,220 additional shares.
• The price is $2.04 per share and $2.039 per pre-funded warrant (the warrant exercise price is $0.001). Gross proceeds are approximately $3.1 million before placement agent fees and expenses. The company expects the closing on September 25, 2026. Dawson James Securities acted as placement agent.

Key Details

• Securities offered: 169,388 common shares + pre-funded warrants to buy up to 1,350,220 shares.
• Price / proceeds: $2.04 per share; $2.039 per pre-funded warrant; ~ $3.1M gross proceeds (before fees).
• Placement agent fee: 8.0% of gross proceeds payable to Dawson James Securities.
• Restrictions & lock-ups: Company agreed to a 6‑month restriction on issuing other equity or equity equivalents (with limited exceptions); directors and executive officers agreed to 90‑day lock-ups after the final prospectus filing.
• Use of proceeds: Pay off existing debt, remainder for working capital and general corporate purposes.
• Other filings: Legal opinion and offering documents are filed as exhibits; press release dated Sept. 24, 2026 included as Exhibit 99.1.

Why It Matters

• The financing provides near-term cash (~$3.1M gross) to retire debt and fund operations, which can help stabilize the company’s liquidity.
• The issuance and potential exercise of pre-funded warrants could materially increase the share count (up to 1.35M additional shares), causing dilution for existing shareholders.
• The 6‑month issuance restriction and 90‑day insider lock-ups limit additional near-term dilution, giving investors some temporary protection from further equity offerings.